Owner Aventis Pharmaceuticals Inc.

Inventors Morse, Clarence C; Keesler Jr., George A.; Yao, Zhengbin; Guo, Yong

Agent Watermark

Pub. Number AU-B-2001285249

PCT Pub. Number WO02/18572

Priority 60/227,647 25.08.00 US; 0103110.3 07.02.01 GB

Filing date 23 August 2001

Wipo publication date 13 March 2002

Acceptance publication date 3 May 2007

C12N 15/09 (2006.01) Mutation or genetic engineering - Recombinant DNA-technology

A61K 38/00 (2006.01) Medicinal preparations containing peptides

A61K 38/46 (2006.01) Medicinal preparations containing peptides

A61K 45/00 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61K 47/42 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - Proteins

A61K 47/48 (2006.01) Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives - the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates

A61P 43/00 (2006.01) Drugs for specific purposes, not provided for in groups

C07K 14/47 (2006.01) Peptides having more than 20 amino acids

C07K 19/00 (2006.01) Hybrid peptides

C12N 5/10 (2006.01) Undifferentiated human, animal or plant cells, e.g. cell lines - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

C12N 15/62 (2006.01) Mutation or genetic engineering - DNA sequences coding for fusion proteins

C12Q 1/02 (2006.01) Measuring or testing processes involving enzymes or micro-organisms - involving viable micro-organisms